Nucleic Acid Therapeutics Initiative (NATi) Call for Proposals

​

Objective

The Nucleic Acid Therapeutics Initiative (NATi) is a National Platform with the mission to build Singapore up as the regional hub and model of excellence for research and clinical translation, and commercialisation of nucleic acid therapeutics (NAT) with epidemic preparedness and resilience. Specifically, NATi focus on the following modalities: antisense oligonucleotides (ASO), small interfering RNA (siRNA) and messenger RNA (mRNA).

THREE SERIES OF CALLS FOR PROPOSALS

The N Series aims to address challenges in the design, delivery, and production of RNA drugs. Each Call for Proposals under the N Series has its own unique set of problem statement(s) to guide project deliverables. All deliverables should be met unless otherwise stated.

The A Series aims to support RNA drug development for defined therapeutic indications. All Calls for Proposals under the A series have specific entry criteria and would require a target product profile.

The T Series aims to leverage emerging opportunities and industry problem statements that have not been captured under the N and A Series. Interested parties are encouraged to contact NATi Coordinating Office (please see contact below) for more details.

Note: There are three active Calls for Proposals - N06, N07 and A01. Please ensure that your submission matches the intended Call for Proposals.

Funding Details

• Realistic quantum and duration corresponding to scope of work.
  

• Please find the maximum quantum for funding as well as maximum duration in the table below for the respective calls.
  

For more details of the call, please refer to the information deck in the zipped file for the respective proposals or visit A*STAR NATi's website here.

Eligibility Criteria

The Lead Investigator and Co-Investigators as defined in Grant Terms and Conditions should:

• Hold a primary appointment in a Singapore publicly funded research institution (such as SingHealth cluster institutions) or an Institute of Higher Learning (IHL). The Lead Investigator must hold a primary appointment of at least 0.7 full-time equivalent (FTE) in Singapore.

• Run a laboratory or research programme which carries out research in Singapore.

• Possess track record of leadership ability in coordinating research programmes and providing mentorship to research teams as well as having productive research outcomes. A track record in securing industry R&D spending (IRS) will be advantageous.
  

Exceptions to the above eligibility criteria will be considered on a case-by-case basis. Please submit a request to the NATi Coordinating Office at enquiry@nati.sg at least 7 days before the closing date of the call for proposals.

Submission

1. Interested applicants are to submit the following completed documents (i.e. proposal form and budget form) through your Host Institution's Research Office to the NATi Coordinating Office at enquiry@nati.sg for by 29 Oct 2024 (Tue), 12PM respectively.
   

    

• 'proposal-template' Word file

• 'proposal-budget-template' Excel file

2. Application must be endorsed by the Host Institution's Research Director in the form of email prior to submission. It is mandatory to append email(s) documenting endorsement from Lead PI's Host Institution in the submission. This is to ensure that there is organisational support for the PI to participate in the grant call. 

Contact Person

If you require further clarification, please send your queries to enquiry@nati.sg. Please allow up to 3 – 5 working days for NATi Coordinating Office to respond.

Additional Information

Please refer to the A*STAR NATi's website here and the following zip file for details.

A Proposals.zip

N Proposals.zip

grant-guidelines.pdf

grant-terms-and-conditions.pdf